Mirum Pharmaceuticals, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) on December 27, 2019, covering events occurring on December 24, 2019. The filing addresses a planned management transition involving the Executive Chairman.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. The document focuses exclusively on executive compensation and role changes.
Material Changes
- Executive Transition: Effective January 1, 2020, Michael Grey resigned as Executive Chairman and executive officer.
- Board Role: Mr. Grey will remain on the Board of Directors as a non-employee director and will serve as Chairman of the Board.
- Compensation Adjustment: Mr. Grey will receive compensation per the non-employee director policy, plus a new annual cash retainer of $65,000 and an option to purchase 100,000 shares of common stock.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or discussion of risks and contingencies. The transition is described as part of a planned management change.
Key Facts for Investor Verification
- Verify the effective date of Michael Grey's resignation as Executive Chairman (January 1, 2020).
- Confirm the total value of the new compensation package, including the $65,000 annual retainer and 100,000 share option grant.
- Review the full text of the Letter Agreement (Exhibit 10.1) for additional terms regarding the transition.
- Check subsequent filings for the appointment of a new Executive Chairman or CEO to replace Mr. Grey's former executive duties.